Protalix Biotherapeutics Inc (NYSE MKT LLC:PLX)

2.23
Delayed Data
As of Apr 24
 +0.01 / +0.45%
Today’s Change
1.53
Today|||52-Week Range
4.20
+21.20%
Year-to-Date
SECTOR
Health Services
INDUSTRY
Services to the Health Industry
MARKET CAP
$208.7M

Company Description

Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. Its drug candidates also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases such as rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing, spondylitis, and plaque psoriasis; and protein for biodefense and other indications. The company was founded on November 30, 1995 and is headquartered in Carmiel, Israel.

Contact Information

Protalix Biotherapeutics, Inc.
2 Snunit Street
Carmiel Haifa 20100
P:(724) 902-8100
Investor Relations:

Employees

Shareholders

Other institutional21.13%
Individual stakeholders19.48%
Mutual fund holders15.00%

Top Executives

Moshe ManorPresident, Chief Executive Officer & Director
Tzvi PalashChief Operating Officer
Yossi MaimonCFO, Secretary, Treasurer, VP & Accounting Officer
Yoseph ShaaltielExecutive Vice President-Research & Development
Yaron NaosVice President-Production

To view my watchlist

Not a member yet?

Sign up now for a free account